Fig 1: Effects of high glucose and recombinant Sclerostin (SCL) on osteocyte remodeling markers in IDG-SW3 cells. (A) Representative images showing osteocytic differentiation over 28 days, including DMP1-GFP fluorescence, ALP staining, and ARS staining. (B) Time-course expression of late osteocytic markers (FGF23, MEPE, Pdpn, Phex, and Sost) over 28 days, presented as relative fold induction. (C) Elevated mRNA expression of Sost, Ctsk, Mmp-13, and Atp6v0d2 in IDG-SW3 cells treated with 20 mM glucose compared to control cells. (D) Upregulation of Ctsk and Mmp-13 mRNA levels in IDG-SW3 cells treated with recombinant SCL compared to vehicle control. Data represent mean ± SD from three independent experiments (n = 3). Statistical significance is indicated (*p < 0.05, **p < 0.01, ****p < 0.0001).